Lv6
1750 积分 2026-01-18 加入
Cost-effectiveness of Adjuvant Pembrolizumab After Nephrectomy for High-risk Renal Cell Carcinoma: Insights for Patient Selection From a Markov Model
28天前
已完结
Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma
29天前
已完结
Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Renal Cell Carcinoma Post-nephrectomy in the United States
1个月前
已完结
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
1个月前
已完结
Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma
1个月前
已完结
MSR125 Methodology for Estimating Equal Value Life-Year for Standard Three-State Partitioned Survival Models
1个月前
已关闭
Mitigating the regressivity of private mechanisms of financing healthcare: An Assessment of 29 countries
2个月前
已关闭
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study
2个月前
已完结
Cost Effectiveness of the First‐in‐Class ARNI (Sacubitril/Valsartan) for the Treatment of Essential Hypertension in a Chinese Setting
2个月前
已完结
Cost-Utility Analysis of TNF-α Inhibitors, B Cell Inhibitors, and JAK Inhibitors Versus csDMARDs for Rheumatoid Arthritis Treatment
2个月前
已完结
皖公网安备34019202002308
